The aim of the current study was to investigate the effectiveness and clinicalfeasibilityofBiyeom-goforthetreatmentofnasalsymptomsassociatedwith rhinitis.
| INTRODUC TI ON
Rhinitisisacommonconditionthataffectsapproximately20%-25% ofthepopulation. 1 Symptomsofrhinitisareoftenignoredbecause they are frequently associated with common cold or disappear spontaneously.However,rhinitiscandisruptsleepandhasanegativeimpactondailyfunctionandperformance 2 ;itcanalsoleadto rhinosinusitis, asthma, otitis media and learning impairment. 3 The economic burden of rhinitis is estimated to be approximately 657 USDperpatienteachyearintheUnitedStates, 4 andtotalhealthcare expenditureassociatedwithallergicrhinitisis272.92millionUSDin theKoreanpopulation. 5 Intranasal herbal therapies, including ointments, drops and sprays, are widely used for treating rhinitis in East Asian countries. 6, 7 Biyeom-go is an herbal ointment that is clinically used in Korean Medicine to improve nasal symptoms associated with rhinitis. Biyeom-go is prepared by the addition of Sophorae Radix and Glycyrrhizae Radix et Rhizoma to the Korean Medicine herbal prescription, Hwanglyeonhaedok-tang (HHT), which consists of Coptidis Rhizoma, Cortex Phellodendri, Scutellariae Radix and GardeniaeFructus. 8, 9 ExperimentalstudieshavesuggestedthatHHThasanti-inflammatory effects by regulating inflammation-related cytokines, includingnitricoxide,prostaglandinE 2 ,interleukin(IL)-6andtumour necrosisfactor(TNF)-α, 10-12 andanti-allergiceffectsbysuppressing eosinophil and histamines. 13, 14 Biyeom-go, which is derived from HHT, is assumed to reduce various symptoms caused by nasal inflammation, including nasal congestion, rhinorrhea and sneezing, butitssafetyandeffectivenessinhumanshavenotbeenthoroughly investigated. The aim of the current study was to investigate the safety, effectiveness and clinical feasibility of Biyeom-go for the treatmentofnasalsymptomsassociatedwithrhinitis. 
| ME THODS

| Study design and ethical considerations
| Participants
Irrespectiveofrhinitissubtypes,thefollowingcriteriawererequired in order to qualify for inclusion in the study: aged 19 
| Interventions
| Outcomes
Thetime-pointsatwhichoutcomesweremeasuredaredetailedinTable S1.TheprimaryoutcomewasTNSS.Mini-rhinoconjunctivitisqualityof lifequestionnaire(RQLQ),nasalendoscopyindex,totalserumimmu-noglobulinE(IgE)levelsandimmunologicfactorsderivedfromnasal lavagefluid(NLF)werealsoexamined.TNSSandmini-RQLQwereassessedateveryvisit(atotalof5times).Thenasalcavitywasassessed
Key points
• Thisprospective,observationalstudyevaluatedtheef-fectivenessandclinicalfeasibilityofBiyeom-goforthe treatmentofnasalsymptomsassociatedwithrhinitis.
• Biyeom-go treatment gradually improved total nasal symptomscoresandmini-rhinoconjunctivitisqualityof lifequestionnairescoresinrhinitispatients.
• IL-2levelssignificantlyincreasedandIL-8,CCL5,CXCL9, CCL2 and CXCL10 levels were significantly reduced in thenasallavagefluidafterBiyeom-gotreatment.
• No serious adverse effects or complications were observed.
usingthenasalendoscopyindexateveryvisit. 15 Photographsofthe anterior nasal cavity were obtained using a KAU-3000 HARMONY ENTmachine(KASAMAENTCo.,Ltd.).Aftercompletionofthestudy, allphotographswereindependentlyscoredbasedonnasalendoscopy index assessment guidelines 15 
| Other measures
Forthesafetyofthestudy,thevitalsignsofparticipantswereexamined at every visit. Information about adverse events (AEs) was providedtoallparticipants.AnyAEspotentiallyrelatedtoBiyeomgowereexamined,andanyassociatedmeasurementsandoutcomes wereassessed. 
| Statistical analysis
| RE SULTS
| Demographic characteristics
FromDecember2016toMarch2017,60patientswereenrolledin the study. Two subsequently dropped out prior to Biyeom-go administration,andtwodroppedoutjustbeforetheend-pointexamination.Atotalof56patientscompletedthestudy,and58patients
were analysed after missing data were imputed for the 2 patients whodroppedoutjustbeforetheend-pointexamination.
Patient characteristics are summarised in Table 1 
| Changes in mini-RQLQ scores
AsBiyeom-gotreatmentprogressed,meanmini-RQLQscoresexhibited significant improvements compared with baseline ( Figure 2A ). 
| Changes in nasal endoscopy index
| Changes in immune biomarkers
TotalserumIgElevelsattheend-pointexaminationweredecreased from baseline, but the difference was not statistically significant 
| Adverse events and concomitant medications
Ofthe58patients,14reportedthefollowingAEs:commoncold (6) *P<.05, **P<.01, ***P < .001 and ****P < .0001 groupisessentialtoassesstheeffects.Therefore,futurerandomised controlledtrialsareneededtoconfirmtheeffectsofBiyeom-go.
| D ISCUSS I ON
| Synopsis of key findings
| Strengths and limitations of the study
| Clinical applicability of the study
The participants included in the present study were treated with Biyeom-go alone to evaluate its clinical effects in rhinitis patients.
Considering its efficacy in terms of improvements in TNSSs, mini-RQLQscores,nasalendoscopyindexandimmunebiomarkerlevels, aswellasacompleteabsenceofseriousAEs,inpatientswithrhinitis; Biyeom-go treatment is feasible for clinical practice and is a safe option for the treatment of rhinitis. This study is the first to examinetheclinicaleffectivenessofBiyeom-go.Ourfindingssuggest that intranasal Biyeom-go administration is safe, and a largescalecontrolledclinicaltrialiswarrantedtodeterminetheefficacy ofBiyeom-goforthemanagementofrhinitissymptoms.
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